Indication
In combination with pembrolizumab for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.
Medicine details
- Medicine name:
- enfortumab vedotin (Padcev
- SMC ID:
- SMC2842
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC